A semi-mechanistic metabolism model of CYP3A substrates in pregnancy: Predicting changes in midazolam and nifedipine pharmacokinetics

S. K. Quinney, A. N. Mohamed, M. F. Hebert, D. M. Haas, S. Clark, J. G. Umans, S. N. Caritis, L. Li

Research output: Contribution to journalArticle

15 Scopus citations


Physiological changes in pregnancy, including changes in body composition and metabolic enzyme activity, can alter drug pharmacokinetics. A semi-mechanistic metabolism model was developed to describe the pharmacokinetics of two cytochrome P450 3A (CYP3A) substrates, midazolam and nifedipine, in obstetrics patients. The model parameters were optimized to fit the data of oral midazolam pharmacokinetics in pregnant women, by increasing CYP3A-induced hepatic metabolism 1.6-fold in the model with no change in gut wall metabolism. Fetal metabolism had a negligible effect on maternal plasma drug concentrations. Validation of the model was performed by applying changes in volume of distribution and metabolism, consistent with those observed for midazolam, to the pharmacokinetics parameters of immediate-release nifedipine in healthy volunteers. The predicted steady-state areas under the concentration-time curve (AUCs) for nifedipine were within 15% of the data observed in pregnant women undergoing treatment for preterm labor. This model predicts the pharmacokinetics of two CYP3A substrates in pregnancy, and may be applicable to other CYP3A substrates as well.

Original languageEnglish (US)
Article numbere2
JournalCPT: Pharmacometrics and Systems Pharmacology
Issue number1
StatePublished - Dec 1 2012


ASJC Scopus subject areas

  • Modeling and Simulation
  • Pharmacology (medical)

Cite this